Oxyntomodulin with GLP-1 and peptide YY cut weight in a 4-week trial

How does oxyntomodulin work?

Oxyntomodulin is a proglucagon-derived peptide released from intestinal L-cells after meals, and it binds both the GLP-1 receptor and the glucagon receptor rather than GLP-1 alone.

A single-dose infusion trial in overweight and obese adults, with and without type 2 diabetes, found that native oxyntomodulin significantly increased insulin secretion during a graded glucose infusion and blunted the glycemic rise ^[6]. The effect was comparable in size to a GLP-1 receptor agonist used as an active comparator, and it happened independent of any weight change ^[6].

That result separates oxyntomodulin's action from being merely a downstream consequence of eating less. The dual-receptor design produces measurable, receptor-driven physiology in humans on its own terms.

Does oxyntomodulin cause weight loss?

Oxyntomodulin produced weight loss in small trials of four weeks or less, but the confirmed data come from infusions that combined it with GLP-1 and peptide YY ^[3].

The oxyntomodulin study most often cited in weight-loss discussions is a four-week randomized trial from 2005 using thrice-daily preprandial subcutaneous injections in overweight and obese volunteers. Secondary literature commonly cites its topline numbers as weight loss in the low single-digit kilograms against a placebo result well under one kilogram; the 2005 paper itself is not among the studies cited below.

In a separate line of research, an ambulatory pump delivered oxyntomodulin, GLP-1, and peptide YY by continuous subcutaneous infusion to obese adults with prediabetes or type 2 diabetes. Over four weeks, the combined infusion produced significantly greater weight loss than saline (4.4 kg vs 2.5 kg) and a significantly larger drop in fructosamine, a marker of average glucose over roughly two to three weeks ^[3].

A related crossover study using the same three-hormone infusion for 10.5 hours a day found a 32% reduction in ad libitum food intake versus placebo, with no significant change in resting energy expenditure ^[5]. A metabolomic subanalysis of the same cohort found a real glucose-lowering effect but no reproduction of the broader metabolic shifts seen with very low-calorie dieting or gastric bypass surgery, so the infusion's physiological footprint is narrower than either comparator ^[4].

The cited human data behind "oxyntomodulin causes weight loss" are small trials of roughly 11 to 21 participants per arm ^[3]⁠^[4], run for four weeks or less, delivered by continuous infusion or frequent injection under close supervision, and always given alongside other gut hormones rather than as a standalone regimen.

Is the weight loss from oxyntomodulin or the other hormones?

The combined infusion studies cannot separate oxyntomodulin's contribution from that of the co-infused GLP-1 and peptide YY. The appetite-suppressing effect has three candidate sources: oxyntomodulin's own receptor activity, the co-infused GLP-1 or peptide YY, or all three acting together.

None of the combined infusion studies tested oxyntomodulin alone against GLP-1 alone in the same protocol, so these designs cannot tell the candidates apart. The human data on PYY and appetite cover one of the co-infused hormones on its own.

Why did oxyntomodulin never become a drug?

None of the cited oxyntomodulin trials tested the unmodified peptide as a self-administered, infrequent-dosing product. Every protocol relied on continuous pump infusion or repeated subcutaneous dosing sustained by clinical staff ^[3]⁠^[4]⁠^[5].

That pattern, repeated across separate trials from 2017 to 2022, is itself evidence for why native oxyntomodulin never reached the market unmodified. If a twice-daily or weekly formulation of native oxyntomodulin had held up, the same line of research would have had reason to test it that way rather than continuing to build infusion rigs.

How is tirzepatide related to oxyntomodulin?

Tirzepatide follows oxyntomodulin's logic with a different receptor pair: tirzepatide activates GIP and GLP-1 receptors, while oxyntomodulin activates GLP-1 and glucagon receptors ^[6]⁠^[7]. After oxyntomodulin, the engineering effort went into longer-acting molecules built around adjacent receptor pairings. The shared logic, adding a second metabolically active receptor to GLP-1 agonism to get more effect than GLP-1 alone, traces to what oxyntomodulin first demonstrated was physiologically achievable in humans ^[6]⁠^[7].

Tirzepatide's phase 1 program established dose-ranging safety and a glycemic proof of concept ^[7]. In phase 3, SURPASS-5, a 40-week randomized trial in 475 people with type 2 diabetes, added tirzepatide to insulin glargine and showed significant reductions in both HbA1c and body weight across all tested doses ^[8]. Mechanistic follow-up attributed part of the insulin-sensitivity improvement to something beyond weight loss alone ^[9]. The tirzepatide trial review covers that program in more detail.

A network meta-analysis covering 816 trials and over 470,000 patients, tirzepatide included, placed GLP-1 receptor agonists among the diabetes drug classes with the strongest mortality benefit evidence, rated high certainty ^[1]. A separate meta-analysis of cancer outcomes across 48 randomized trials found no significant increase in thyroid, pancreatic, breast, or kidney cancer risk with GLP-1 receptor agonists and dual agonists, at moderate certainty ^[2].

None of that infrastructure exists for oxyntomodulin itself: no safety data at scale, no cardiometabolic outcome data, and no cancer surveillance.

What is still unknown about oxyntomodulin?

Oxyntomodulin's human evidence stops at four weeks and at supervised research settings, which leaves three gaps:

• Durability. Whether unmodified oxyntomodulin, dosed the way any cited trial dosed it, holds up over months rather than weeks is not established; every cited trial ran four weeks or less ^[3]⁠^[4]⁠^[5]⁠^[6].
• Attribution. The combined infusion designs cannot separate oxyntomodulin's effect from the effects of GLP-1 and peptide YY.
• Long-term safety. No long-term safety data or large-cohort trial exists for oxyntomodulin as a standalone molecule, and none of the cited studies reports a regulatory review.

Anyone using oxyntomodulin today, outside a research infusion protocol, is operating with none of the evidence base that supports the engineered co-agonists it helped inspire.